STAT
NOVEMBER 1, 2024
In 2022, Noha Aboelata noticed something troubling. The founding CEO of a health clinic that serves a predominantly Black and brown population, she realized that the racial biases built in pulse oximeters were hurting her patients in Oakland, California. The devices overestimate blood oxygen in people with darker skin tones, making them appear healthier than they are.
Fierce Pharma
NOVEMBER 1, 2024
With a positive readout for metabolic dysfunction-associated steatohepatitis (MASH) now in the bag, Novo Nordisk is gearing up to pursue yet another indication for its star GLP-1 medicine semagluti | Novo Nordisk on Friday revealed that its star GLP-1 semaglutide met the mark in a late-stage MASH study. The positive results build on the thesis that GLP-1s could become a foundational piece in the treatment paradigm for the fatty liver disease, according to analysts at William Blair.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
STAT
NOVEMBER 1, 2024
Novo Nordisk’s weight loss drug Wegovy helped people with a fatty liver disease called MASH experience improvements in liver scarring and achieve symptom resolution, results the company sees as supporting regulatory approval. After 72 weeks in a Phase 3 trial, 37% of patients on Wegovy experienced an improvement in liver scarring, or fibrosis, with no worsening of their disease.
Pharmacy Times
NOVEMBER 1, 2024
ASHP investigators determined the severity and impact of ongoing drug shortages, with approximately 99% of respondents reporting that they experienced a shortage.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Drug Topics
NOVEMBER 1, 2024
Researchers from Celltrion USA presented their post hoc analysis from the LIBERTY studies at the American College of Gastroenterology 2024 Annual Scientific Meeting.
STAT
NOVEMBER 1, 2024
If you are a doctor, the odds are that your patients think or do things you don’t agree with. Nearly half of Americans believe at least one health-related conspiracy theory, people routinely lie to their doctors about how much they drink, and many act on health information they find on social media without checking with their doctor first.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
STAT
NOVEMBER 1, 2024
Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here. After being far from the first person to roll down the social media clips → Gamechanger → Dimension 20 pipeline, I played my first game of Dungeons & Dragons this past weekend. (It was fabulous.
pharmaphorum
NOVEMBER 1, 2024
With artificial intelligence technologies for healthcare on the rise, UK health technology assessment (HTA) agency NICE has published an economic evaluation standard that it says will help inform coverage and reimbursement decisions.
STAT
NOVEMBER 1, 2024
It’s been 13 years since the term “precision medicine” was coined , and its promise — the ability to treat the right patient with the right medicine in the right dose at the right time — remains as compelling as ever. But we haven’t yet fulfilled this promise. Why? In my previous role as head of precision medicine at Novartis, I realized the biggest challenge to making precision medicine a reality was not the development of the medicines themselves
Fierce Pharma
NOVEMBER 1, 2024
Despite its unique ability to block sodium-glucose linked transporter 2 (SGLT2) in the kidneys and SGLT1 in the intestines, Lexicon’s Zynquista (sotagliflozin) has had difficulty negotiating r | Despite its unique ability to block sodium-glucose linked transporter 2 (SGLT2) in the kidneys and SGLT1 in the intestines, Lexicon’s Zynquista (sotagliflozin) has had difficulty negotiating regulatory hurdles.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
STAT
NOVEMBER 1, 2024
WASHINGTON — The hospital industry has pushed back against Medicare payment reforms for years, arguing that the policies would financially hurt rural hospitals. Two key senators on Friday released a plan to get around that issue by reinvesting some of the money saved from payment reforms to help rural and safety-net hospitals. Hospitals that keep providing services like trauma centers, labor and delivery units, and burn units would get financial bonuses, too.
Pharmaceutical Technology
NOVEMBER 1, 2024
Verastem Oncology has concluded the rolling submission of a new drug application (NDA) to the US Food and Drug Administration (FDA) for a combination of avutometinib and defactinib for low-grade serous ovarian cancer (LGSOC).
PharmaVoice
NOVEMBER 1, 2024
Almost a year after two historic approvals, Pfizer is pulling a sickle cell disease treatment from the market, and the outlook for patients feels shakier. But there’s still hope in the pipeline.
pharmaphorum
NOVEMBER 1, 2024
FDA advisors vote against Lexicon Pharma's type 1 diabetes and chronic kidney disease therapy sotagliflozin ahead of December verdict
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
STAT
NOVEMBER 1, 2024
Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us, and we’ll share it with others. That’s right. Send us your changes, and we’ll find a home for them. Don’t be shy. Everyone wants to know who is coming and going. And here is our regular feature in which we highlight a different person each week.
Drug Topics
NOVEMBER 1, 2024
Learn how one pharmacy used RxCash+ to lessen the stress of cash pricing and spend more time on patient care.
Fierce Pharma
NOVEMBER 1, 2024
Just a few months into a new launch in chronic inflammatory demyelinating polyneuropathy (CIDP), agrenx’ Vyvgart is already making headway in the rare disease space, just one of the long-term growt | So far, argenx's Vyvgart has reached 300 patients with chronic inflammatory demyelinating polyneuropathy (CIDP) after securing an FDA approval in the disease in late June.
STAT
NOVEMBER 1, 2024
This story first appeared in The Readout newsletter. Sign up for The Readout and receive STAT’s award-winning biotech news delivered straight to your inbox. Morning! Today, we discuss Madrigal’s impressive launch of its MASH drug Rezdiffra, see psychedelics player Compass Pathways shed 30% of its staff, and more.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Pharmacy Times
NOVEMBER 1, 2024
Intravenous immunoglobulin prescriptions deemed non-compliant according to French national guidelines were more common in younger patients.
STAT
NOVEMBER 1, 2024
And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is still shaping up, but will almost certainly include tidying up the Pharmalot grounds, promenading with the official mascots, and catching up on our reading. We also hope to hold another listening party, where the rotation will likely include this , this , this , this and this.
Drug Topics
NOVEMBER 1, 2024
In a recent clinical trial, weekly semaglutide demonstrated promise as a nonsurgical, nonopioid intervention for reducing knee osteoarthritis pain.
Pharmaceutical Commerce
NOVEMBER 1, 2024
Analysis finds that while basic Part D coverage costs have decreased by 4%, mid- and high-tier plans have seen hikes of 4% and 21%, respectively.
Fierce Healthcare
NOVEMBER 1, 2024
Health tech company Artera built new artificial intelligence products to help administrative staff communicate with patients faster while also easing their workload. | Health tech company Artera built new artificial intelligence products to help administrative staff communicate with patients faster while also easing their workload.
Outsourcing Pharma
NOVEMBER 1, 2024
A new case study released by AllazoHealth reveals that a leading rare disease pharmaceutical company achieved a 10.4% increase in therapy initiation, driven by AI-enabled patient outreach and personalized communications.
Drug Topics
NOVEMBER 1, 2024
A conversation with Melody Hartzler, PharmD, at the 2024 National Community Pharmacists Association Annual Convention and Expo.
Pharmacy Times
NOVEMBER 1, 2024
Carrie Koenigsfeld, PharmD, FAPhA, discusses how pharmacists can incorporate RSV vaccination education and recommendations into daily pharmacy workflows, including prescription pick-ups, consultations, and routine MTM sessions.
Fierce Healthcare
NOVEMBER 1, 2024
Private equity firm Francisco Partners plans to buy medical software company AdvancedMD from Global Payments for $1.125 billion dollars, the companies announced Wednesday. | Private equity firm Francisco Partners plans to buy medical software company AdvancedMD from Global Payments for $1.125 billion dollars, the companies announced Wednesday.
Pharmacy Times
NOVEMBER 1, 2024
Panelists discuss how subcutaneous (SC) administration of drugs like daratumumab offers advantages over intravenous (IV) administration in terms of reduced health care resource utilization, improved patient convenience, and potentially better treatment adherence, while also considering potential drawbacks such as injection site reactions and the need for proper training in SC administration techniques.
Outsourcing Pharma
NOVEMBER 1, 2024
At CPHI Milan 2024, Abzena showcased its latest innovations in cell line development and ADC manufacturing, featuring the advanced AbZelectPRO platform and ThioBridge linker technology.
Pharmacy Times
NOVEMBER 1, 2024
Panelists discuss how pharmacists play a crucial role throughout the multiple myeloma patient journey, from diagnosis to treatment, by contributing to medication management, patient education, adverse effect monitoring, and the development and implementation of order sets and clinical pathways within electronic medical record systems, thereby enhancing treatment efficacy and patient safety.
Fierce Pharma
NOVEMBER 1, 2024
After prior settlements, Apotex and Heritage hand over a combined $49M to resolve longstanding price-fixing claims fkansteiner Fri, 11/01/2024 - 10:19
Pharmacy Times
NOVEMBER 1, 2024
In the results, 31% of patients maintained undetectable measurable residual disease 4 years after treatment.
Fierce Healthcare
NOVEMBER 1, 2024
Everyone agrees primary care is crucial to a functioning healthcare ecosystem and to a healthy society. | Everyone agrees primary care is crucial, yet it isn't working as well as it should be. A panel of primary care executives considered the drawbacks of the traditional model and opportunities for the sector at HLTH last month.
Expert insights. Personalized for you.
135 
Let's personalize your content